Literature DB >> 15634023

Synthesis and biological properties of new stilbene derivatives of resveratrol as new selective aryl hydrocarbon modulators.

Philippe de Medina1, Robert Casper, Jean-François Savouret, Marc Poirot.   

Abstract

We developed new stilbene derivatives of resveratrol (E)-1-(4'-hydroxyphenyl)-2-(3,5-dihydroxyphenyl)ethene) selective for AhR and devoid of affinity for ER. Among the 24 stilbenes synthesized, all display a higher affinity than resveratrol for AhR. (E)-1-(4'-Trifluoromethylphenyl)-2-(3,5-ditrifluoromethylphenyl)ethene (4e), (E)-1-(4'-methoxyphenyl)-2-(3,5-dichlorophenyl)ethene (4j), and (E)-1-(4'-chlorophenyl)-2-(3,5-dichlorophenyl)ethene (4b) are selective, high-affinity AhR antagonists with, respective, K(i)s of 2.1, 1.4, and 1.2 nM. (E)-1-(4'-Trifluoromethylphenyl)-2-(3,5-dichlorophenyl)ethene (4i) displays a K(i) of 0.2 nM and is a selective and high-affinity agonist on AhR.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15634023     DOI: 10.1021/jm0498194

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  15 in total

1.  Non-nucleoside hepatitis B virus polymerase inhibitors identified by an in vitro polymerase elongation assay.

Authors:  Shogo Nakajima; Koichi Watashi; Kento Fukano; Senko Tsukuda; Kousho Wakae; Hideki Aizaki; Masamichi Muramatsu; Takaji Wakita; Tetsuya Toyoda
Journal:  J Gastroenterol       Date:  2019-11-25       Impact factor: 7.527

2.  Resveratrol (trans-3,5,4'-trihydroxystilbene) suppresses EL4 tumor growth by induction of apoptosis involving reciprocal regulation of SIRT1 and NF-κB.

Authors:  Narendra P Singh; Udai P Singh; Venkatesh L Hegde; Hongbing Guan; Lorne Hofseth; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Mol Nutr Food Res       Date:  2011-04-26       Impact factor: 5.914

3.  Resveratrol prevents epigenetic silencing of BRCA-1 by the aromatic hydrocarbon receptor in human breast cancer cells.

Authors:  Andreas J Papoutsis; Sarah D Lamore; Georg T Wondrak; Ornella I Selmin; Donato F Romagnolo
Journal:  J Nutr       Date:  2010-07-14       Impact factor: 4.798

4.  Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor.

Authors:  Narendra P Singh; Venkatesh L Hegde; Lorne J Hofseth; Mitzi Nagarkatti; Prakash Nagarkatti
Journal:  Mol Pharmacol       Date:  2007-09-14       Impact factor: 4.436

5.  Potential of resveratrol analogues as antagonists of osteoclasts and promoters of osteoblasts.

Authors:  Katarzyna Kupisiewicz; Patrice Boissy; Basem M Abdallah; Frederik Dagnaes Hansen; Reinhold G Erben; Jean-Francois Savouret; Kent Søe; Thomas L Andersen; Torben Plesner; Jean-Marie Delaisse
Journal:  Calcif Tissue Int       Date:  2010-09-15       Impact factor: 4.333

6.  The Aryl Hydrocarbon Receptor: A Target for Breast Cancer Therapy.

Authors:  Joann B Powell; Gennifer D Goode; Sakina E Eltom
Journal:  J Cancer Ther       Date:  2013-09

Review 7.  Recent advances in the development of AHR antagonists in immuno-oncology.

Authors:  Lijun Sun
Journal:  RSC Med Chem       Date:  2021-04-06

8.  Antiviral bioactivity of resveratrol against Zika virus infection in human retinal pigment epithelial cells.

Authors:  Constanza A Russo; María F Torti; Agustina Alaimo; Cybele C García; Agostina B Marquez; Claudia S Sepúlveda
Journal:  Mol Biol Rep       Date:  2021-07-20       Impact factor: 2.316

9.  Docking study of triphenylphosphonium cations as estrogen receptor alpha modulators.

Authors:  Joseph P Salisbury; John C Williams
Journal:  Bioinformation       Date:  2009-02-28

10.  Experimental Data Extraction and in Silico Prediction of the Estrogenic Activity of Renewable Replacements for Bisphenol A.

Authors:  Huixiao Hong; Benjamin G Harvey; Giuseppe R Palmese; Joseph F Stanzione; Hui Wen Ng; Sugunadevi Sakkiah; Weida Tong; Joshua M Sadler
Journal:  Int J Environ Res Public Health       Date:  2016-07-12       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.